Preview

Научно-практическая ревматология

Расширенный поиск

Этодолак: хорошо известен и активно используется в разных странах мира. Пора бы и нам?

https://doi.org/10.14412/1995-4484-2019-468-473

Полный текст:

Аннотация

Этодолак – нестероидный противовоспалительный препарат (НПВП), умеренно селективный ингибитор циклооксигеназы-2, который уже более 30 лет используется в клинической практике как универсальное обезболивающее и противовоспалительное средство. Этодолак хорошо зарекомендовал себя при купировании острой боли, связанной с травмами и хирургическими вмешательствами (в частности, в стоматологии). Однако основной «точкой приложения» этодолака является длительный контроль боли при хронических ревматических заболеваниях, таких как остеоартрит и ревматоидный артрит. По данным многочисленных клинических исследований, этодолак как минимум не уступает по лечебному действию многим другим популярным представителям группы НПВП или превосходит их. Основным достоинством этодолака является низкая частота осложнений со стороны желудочно-кишечного тракта. В настоящем обзоре представлены основные данные литературы об эффективности и безопасности этодолака.

Об авторе

А. Е. Каратеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



Список литературы

1. Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65 doi: 10.14412/1995-4484-2016-247-265

2. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. Am Psychol. 2014 Feb-Mar;69(2):119-30. doi: 10.1037/a0035514

3. http://www.gks.ru/free_doc/doc_2017/zdrav17.pdf

4. Ali A, Arif AW, Bhan C, et al. Managing Chronic Pain in the Elderly: An Overview of the Recent Therapeutic Advancements. Cureus. 2018 Sep 13;10(9):e3293. doi: 10.7759/cureus.3293

5. Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(Прил. 1):1-29 doi: 10.14412/1995-4484-2018-1-29

6. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci (www.cspsCanada.org). 2013;16(5):821-47. doi: 10.18433/J3VW2F

7. Balfour JA, Buckley MM. Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs. 1991 Aug;42(2):274-99. doi: 10.2165/00003495-199142020-00008

8. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8. doi: 10.1073/pnas.96.13.7563

9. Brocks DR, Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet. 1994 Apr;26(4):259-74. doi: 10.2165/00003088-199426040-00003

10. https://www.ndrugs.com/?s=etodolac&showfull=1

11. Tirunagari SK, Derry S, Moore RA, McQuay HJ. Single dose oral etodolac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007357. doi: 10.1002/14651858.CD007357.pub2

12. Hersh EV, Levin LM, Cooper SA, et al. Conventional and extended-release etodolac for postsurgical dental pain. Clin Ther. 1999 Aug;21(8):1333-42. doi: 10.1016/S0149-2918(99)80034-4

13. Akbulut N, Üstü ner E, Atakan C, Cö lok G. Comparison of the effect of naproxen, etodolac and diclofenac on postoperative sequels following third molar surgery: a randomised, double-blind, crossover study. Med Oral Patol Oral Cir Bucal. 2014 Mar 1;19(2):e149-56. doi: 10.4317/medoral.19518

14. Comfort MB, Tse AS, Tsang AC, McGrath C. A study of the comparative efficacy of three common analgesics in the control of pain after third molar surgery under local anaesthesia. Aust Dent J. 2002 Dec;47(4):327-30. doi: 10.1111/j.1834-7819.2002.tb00546.x

15. Silva de Oliveira JC, Grossi de Oliveira GA, Bassi AP. Comparative Assessment of the Effect of Ibuprofen and Etodolac on Edema, Trismus, and Pain in Lower Third Molar Surgery: A Randomized Clinical Trial. J Oral Maxillofac Surg. 2016 Aug;74(8):1524-30. doi: 10.1016/j.joms.2016.04.003. Epub 2016 Apr 13.

16. Lin S, Levin L, Emodi O, et al. Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jun;101(6):814-7. Epub 2006 Apr 17.

17. Casey R, Zadra J, Khonsari H. A comparison of etodolac (Ultradol) with acetaminophen plus codeine (Tylenol #3) in controlling post-surgical pain in vasectomy patients. Curr Med Res Opin. 1997;13(10):555-63. doi: 10.1185/03007999709113329

18. Bellamy N. Etodolac in the management of pain: a clinical review of a multipurpose analgesic. Inflammopharmacology. 1997;5(2):139-52. doi: 10.1007/s10787-997-0023-8

19. Ishiguro N, Hanaoka A, Okada T, Ito M. Efficacy and safety of celecoxib compared with placebo and etodolac for acute postoperative pain: a multicenter, double-blind, randomized, parallel-group, controlled trial. Nagoya J Med Sci. 2015 Feb;77(1-2):81-93.

20. Pareek A, Chandurkar N, Gupta A, et al. Comparative evaluation of efficacy and safety of etodolac and diclofenac sodium injection in patients with postoperative orthopedic pain. Curr Med Res Opin. 2011 Nov;27(11):2107-15. doi: 10.1185/03007995.2011.619179. Epub 2011 Sep 23.

21. D'Hooghe M. Double-blind, parallel-group evaluation of etodolac and naproxen in patients with acute sports injuries. Clin Ther. 1992 Jul-Aug;14(4):507-16.

22. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423-9. doi: 10.1185/03007999109111513

23. Hatori M, Kokubun S. Clinical use of etodolac for the treatment of lumbar disc herniation. Curr Med Res Opin. 1999;15(3):193-201. doi: 10.1185/03007999909114091

24. Arriagada M, Arinoviche R. Etodolac versus piroxicam in the treatment of acute lumbago. Double-blind study. Rev Med Chil. 1992 Jan;120(1):54-8.

25. Porzio F. Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. Rheumatol Int. 1993;13(2 Suppl):S19-24. doi: 10.1007/BF00290280

26. Porzio F. Meta-analysis of two double-blind comparative studies with the sustained-release form of etodolac in rheumatoid arthritis. Rheumatol Int. 1993;13(2 Suppl):S25-30. doi: 10.1007/BF00290281

27. Spencer-Green G. Low dose etodolac in rheumatoid arthritis: a review of early studies. J Rheumatol Suppl. 1997 Feb;47:3-9; discussion 48-50.

28. Schnitzer TJ, Constantine G. Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. J Rheumatol Suppl. 1997 Feb;47:23-31.

29. Lonauer G, Tisscher JR, Lim HG, Bijlsma JW. Double-blind comparison of etodolac and diclofenac in patients with rheumatoid arthritis. Curr Med Res Opin. 1993;13(2):70-7. doi: 10.1185/03007999309111535

30. Neustadt DH. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl. 1997 Feb;47:17-22.

31. Paulus HE, Di Primeo D, Sharp JT, et al. Long-Term Etodolac Study Investigators. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs. J Rheumatol. 2004 Mar;31(3):470-81.

32. Grisanti AM, Vaz AA, Samara AM. Comparison of etodolac and diclofenac in osteoarthritis of the knee. Clin Ther. 1992 Nov-Dec;14(6):791-800.

33. Lü cker PW, Pawlowski C, Friedrich I, et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm. 1994;14(2):29-38.

34. Dore R, Ballard I, Constantine G, McDonald P. Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study. Clin Ther. 1995 Jul-Aug;17(4):656-66. doi: 10.1016/0149-2918(95)80042-5

35. Perpignano G, Bogliolo A, Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res. 1994;14(5-6):203-16.

36. Dick WC, Bulstra S, Schardijn GH, Feenstra RM. Safety and efficacy of etodolac compared with piroxicam in patients with degenerative joint disease of the knee. Clin Ther. 1992 Jul-Aug;14(4):517-26.

37. Benhamou CL. Large-scale open trials with etodolac (Lodine) in France: an assessment of safety. Rheumatol Int. 1990;10 Suppl:29-34. doi: 10.1007/BF02274753

38. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii. doi: 10.3310/hta12110

39. Russell RI. Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int. 1990;10 Suppl:17-21. doi: 10.1007/BF02274751

40. Van Eeden A, Schotborgh RH, Tytgat GN. An endoscopic evaluation of the effects of etodolac and diclofenac on the gastric and duodenal mucosa. Clin Ther. 1990 Nov-Dec;12(6):496-502.

41. Laine L, Sloane R, Ferretti M, Cominelli F. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production. Gastrointest Endosc. 1995 Nov;42(5):428-33. doi: 10.1016/S0016-5107(95)70045-5

42. Taha AS, McLaughlin S, Sturrock RD, Russell RI. Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolacand naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol. 1989 Aug;28(4):329-32. doi: 10.1093/rheumatology/28.4.329

43. Leese P. Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss. Curr Med Res Opin. 1992;13(1):13-20. doi: 10.1185/03007999209115217

44. Varas-Lorenzo C, Riera-Guardia N, Calingaert B,et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70. doi: 10.1002/pds.3437

45. Brater DC. Evaluation of etodolac in subjects with renal impairment. Eur J Rheumatol Inflamm. 1990;10(1):44-55.

46. Svendsen KB, Bech JN, Sоrensen TB, Pedersen EB. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000 Aug;56(5):383-8. doi: 10.1007/s002280000161

47. Brater DC, Brown-Cartwright D, Anderson SA, Uaamnuichai M. Effect of high-dose etodolac on renal function. Clin Pharmacol Ther. 1987 Sep;42(3):283-9. doi: 10.1038/clpt.1987.148


Для цитирования:


Каратеев А.Е. Этодолак: хорошо известен и активно используется в разных странах мира. Пора бы и нам? Научно-практическая ревматология. 2019;57(4):468-473. https://doi.org/10.14412/1995-4484-2019-468-473

For citation:


Karateev A.E. ETODOLAC, A WELL KNOWN AND ACTIVELY USED DRUG IN DIFFERENT COUNTRIES OF THE WORLD. WOULD IT BE TIME FOR US? Rheumatology Science and Practice. 2019;57(4):468-473. (In Russ.) https://doi.org/10.14412/1995-4484-2019-468-473

Просмотров: 126


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)